. . . as a benchmark, you might consider OPTR . . . it's a biotech with an approved antibiotic for c-difficile . . . its current market capitalization is $570 million -- that same m.c. for TSRX would put its share price at about $12 . . .
With good data in and no debt with what 80 million cash?? This should be at $8 by now and testing new all time highs IMHO. Patients.........this will run after everyone who wants in (big fish) is in.